Study drug for infection-related lung failure in adults
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You developed ARDS after an infection within the last 7 days, based on chest imaging (usually X-ray/scan) showing problems in both lungs
- Your breathing problem started recently—moderate to severe ARDS symptoms for 48 hours or less—often needing breathing support like a ventilator, CPAP/BiPAP, or high-flow oxygen
- You can sign consent yourself or have a legally allowed person sign for you
- If you can become pregnant or have a partner who could, you must use two reliable birth-control methods (and you cannot donate sperm/eggs during the study and for 3 months after)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
This trial tests an experimental drug called R-3750 for people with a severe lung condition called ARDS that has not improved after at least a week. The drug is given through a tube into the stomach, and the goal is to see if it can help the lungs recover.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests whether erythropoietin (EPO), a medicine that affects red blood cell production, can help clear extra fluid from the lungs in people with acute respiratory distress syndrome (ARDS). If it works, it could improve breathing and reduce lung fluid buildup during critical illness.
This study tests whether a customized breathing machine approach ("precision ventilation") is better than usual care for patients with ARDS. The goal is to improve oxygen levels and recovery while avoiding lung damage.
This trial tests a new medicine called GKL-006RTU for people with moderate to severe ARDS caused by an infection. The goal is to see if it is safe and helps improve breathing and recovery.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.